دورية أكاديمية

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus phaselenalidomide: II HOVON trial results of a multicenter

التفاصيل البيبلوغرافية
العنوان: Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus phaselenalidomide: II HOVON trial results of a multicenter
المؤلفون: Chamuleau, ME, Burggraaff, C.N., Nijland, M, Bakunina, K., Mous, R., Lugtenburg, P.J. (Pieternella), Dierickx, D. (Daan), Imhoff, G. (Gustaaf) van, Vermaat, J.S. (Joost), Marijt, E.A.F., Visser, O. (Oane), Mandigers, C., Bilgin, YM, Beeker, A. (Aart), Durian, MF, Rees, B.P. (Bastiaan) van, Bohmer, L.H., Tick, L.W. (Lidwine), Boersma, R. S., Snijders, T.J.F., Schouten, HC, Koene, H.R. (Harry), de Jongh, E., Hijmering, N., Diepstra, A, Berg, A. (Andrea) von, Arens, A. (Anne), Huijbregts, J., Hoekstra, O, Zijlstra, J.M. (Josée), Jong, D. de, Kersten, M.J. (Marie José)
المصدر: Haematologica vol. 105 no. 12, pp. 2805-2812
سنة النشر: 2020
المجموعة: RePub - Publications from Erasmus University, Rotterdam
الوصف: P atients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients without MYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL. A phase II trial was conducted evaluating the efficacy of lenalidomide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in newly diagnosed MYC+ LBCL patients identified through a nationwide MYCFISH screening program. The primary endpoint was complete metabolic response (CMR) on centrally reviewed 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET)-computer tomography (CT)-scan at end-of-treatment. Secondary endpoints were overall survival (OS), disease free survival (DFS) and event-free survival (EFS). Eighty-two patients with stage II-IV MYC+ LBCL were treated with six cycles of R2CHOP. At end of treatment, 67% (95% Confidence interval [CI]: 58-75) of the patients reached CMR. With a median follow-up of 25.4 months, 2-year estimates for OS, DFS, EFS were 73% (95% CI: 62-82), 75% (95% CI: 63-84) and 63% change to: (95% CI: 52-73) respectively. In this prospective trial for newly diagnosed MYC+ LBCL patients, we found that administering R2CHOP was safe, and yields comparable CMR and survival rates as in studies applying more intensive chemotherapy regimens. Hence, these findings offer new prospects for MYC+ LBCL patients and warrant comparison in prospective randomized clinical trials. This trial was registered at www.clinicaltrialsregister.eu (#2014-002654-39).
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
العلاقة: https://repub.eur.nl/pub/133590Test; urn:hdl:1765/133590
DOI: 10.3324/haematol.2019.238162
الإتاحة: https://doi.org/10.3324/haematol.2019.238162Test
https://repub.eur.nl/pub/133590Test
رقم الانضمام: edsbas.DA770799
قاعدة البيانات: BASE